Physician profile
Laura Katz
NPI 1710183777
$2,243.06
in general payments reported to CMS, 2019-2025
9 companies · $278 in 2025
The $278 reported for 2025 was more than what 78% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $327 · 2021: $371 · 2022: $148 · 2023: $313 · 2024: $335 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $892.82 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Ironshore Pharmaceuticals INC. | $607.53 | 2019-2024 | Jornay Pm |
| Corium, LLC | $442.91 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $112.76 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $67.34 | 2020 | |
| Shire North American Group INC | $43.93 | 2019 | |
| Vertical Pharmaceuticals, LLC | $39.38 | 2019-2025 | Relexxii |
| Adlon Therapeutics L.P. | $20.52 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.87 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.